These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 25144360

  • 1. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M.
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [Abstract] [Full Text] [Related]

  • 2. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.
    PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ.
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [Abstract] [Full Text] [Related]

  • 4. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.
    Pudney VA, Leese AM, Rickinson AB, Hislop AD.
    J Exp Med; 2005 Feb 07; 201(3):349-60. PubMed ID: 15684323
    [Abstract] [Full Text] [Related]

  • 5. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
    Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M.
    J Virol; 2016 Jan 01; 90(1):356-67. PubMed ID: 26468525
    [Abstract] [Full Text] [Related]

  • 6. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
    Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R.
    PLoS Pathog; 2012 Jan 01; 8(5):e1002704. PubMed ID: 22615564
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
    Long HM, Leese AM, Chagoury OL, Connerty SR, Quarcoopome J, Quinn LL, Shannon-Lowe C, Rickinson AB.
    J Immunol; 2011 Jul 01; 187(1):92-101. PubMed ID: 21622860
    [Abstract] [Full Text] [Related]

  • 8. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
    Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME.
    J Immunol; 2009 Feb 15; 182(4):2313-24. PubMed ID: 19201886
    [Abstract] [Full Text] [Related]

  • 9. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J.
    PLoS One; 2007 Jul 04; 2(7):e583. PubMed ID: 17611619
    [Abstract] [Full Text] [Related]

  • 10. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.
    Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, Wiertz EJ, Rowe M.
    PLoS Pathog; 2009 Jan 04; 5(1):e1000255. PubMed ID: 19119421
    [Abstract] [Full Text] [Related]

  • 11. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 04; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 13. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.
    Griffin BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, Wang F, Ressing ME, Wiertz E.
    J Immunol; 2013 Feb 15; 190(4):1672-84. PubMed ID: 23315076
    [Abstract] [Full Text] [Related]

  • 14. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
    Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR.
    J Virol; 2009 Mar 15; 83(6):2783-8. PubMed ID: 19129449
    [Abstract] [Full Text] [Related]

  • 15. The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.
    Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.
    PLoS Pathog; 2016 Apr 15; 12(4):e1005550. PubMed ID: 27077376
    [Abstract] [Full Text] [Related]

  • 16. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
    Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C.
    J Exp Med; 2001 Feb 05; 193(3):405-11. PubMed ID: 11157061
    [Abstract] [Full Text] [Related]

  • 17. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
    Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, Wiertz EJ, Rowe M.
    J Immunol; 2005 Jun 01; 174(11):6829-38. PubMed ID: 15905524
    [Abstract] [Full Text] [Related]

  • 18. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH, Wirth LJ, Posner M, Wang F.
    Proc Natl Acad Sci U S A; 2009 Mar 03; 106(9):3318-23. PubMed ID: 19211798
    [Abstract] [Full Text] [Related]

  • 19. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
    van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM.
    Mult Scler; 2016 Mar 03; 22(3):279-91. PubMed ID: 26041797
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
    Almohammed R, Osborn K, Ramasubramanyan S, Perez-Fernandez IBN, Godfrey A, Mancini EJ, Sinclair AJ.
    J Gen Virol; 2018 Jun 03; 99(6):805-817. PubMed ID: 29580369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.